chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient did not have any  common signs or symptoms associated to the vaccine. The Health Department had questions of the temperatures that the vaccine was exposed. There was incident on 9/26/2022 at 08:27 am 9/27/2022 at 11:27 am to where the refrigerator thermometer was connect to the frezeer and the frezeer thermometer was connected to the refrigerator. The temperatures recorders for the refrigerator were  in a range of 4.2 to 4.8 degree centigrades. There was not any visible sign of damage to the vaccine. The Health Department ordered to discard the two vials but was not done inmmediately. The vials were label, do not use but by confusion, the girl was vaccinated with this vaccine. There was a posterior incident and the Department of Health order that another lot could be used and the personnel used the one that should not be used by mistake.
Patient felt dizzy. Patient was out the store when fell over his left knee. He was consulted and haven't take food for a long period of time before being vaccinated (approx 7 hours). Apparently, it was related to a low level of blood glucose.
received the sanofi flu shot and then passed away one month later from pneumonia; both illnesses that attack the lungs; Initial information was received on 15-Sep-2023 regarding an unsolicited valid serious case received from a consumer/non-health-care professional.  This case involves an unknown age male patient who received the sanofi flu shot and then passed away one month later from pneumonia and both illnesses that attack the lungs after receiving vaccine influenza vaccine.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  On an unknown date, the patient received a unknown dose of suspect influenza vaccine produced by unknown manufacturer (formulation, strength, expiry date, lot number not reported) via unknown route in unknown administration site for prophylactic vaccination (Immunization). The information on batch number was requested.  On an unknown date the patient developed a serious event of received the sanofi flu shot and then passed away one month later from pneumonia (unknown latency) following the administration of influenza vaccine.   On an unknown date the patient developed a non-serious event of both illnesses that attack the lungs (illness) (unknown latency) following the administration of influenza vaccine. Final diagnosis was (fatal) received the sanofi flu shot and then passed away one month later from pneumonia.  Action taken with influenza vaccine was not applicable.  It was not reported if the patient received a corrective treatment for the events (received the sanofi flu shot and then passed away one month later from pneumonia, both illnesses that attack the lungs).  At time of reporting, the outcome was Fatal for the event received the sanofi flu shot and then passed away one month later from pneumonia and was Unknown for the event both illnesses that attack the lungs. It is unknown if an autopsy was done. The cause of death was reported as Pneumonia.  Seriousness criteria : This event was assessed as medically significant and was leading to death (received the sanofi flu shot and then passed away one month later from pneumonia) .; Sender's Comments: Sanofi Company Comment dated 21-Sep-2023: This case involves an unknown age male patient who received the sanofi flu shot and then passed away one month later from pneumonia and both illnesses that attack the lungs after receiving vaccine influenza vaccine. Further information regarding concurrent condition during vaccination, previous vaccination, concomitant medication and tolerance, allergic history, laboratory investigations excluding alternative etiologies for the reported event are needed to fully assess this case. Based upon the reported information, with no time to onset, the role of the individual suspect vaccine cannot be assessed. Case will be re-evaluated post further update on the missing information; Reported Cause(s) of Death: received the sanofi flu shot and then passed away one month later from pneumonia
Redness on left deltoid 3 3/4 in wide and 4 1/2 in long, warm to touch.  Parent states it hurts her.
PATIENT RECEIVED VACCINE FROM OUTSIDE SOURCE CHRONIC HYPOTENSION 8/2/2022 &  8/22/2022 -- RECURRENCE OF SAME SYMPTOMS
Approximately two minutes after vaccine injection, pt started to feel dizzy, saw spots, felt like she was going to pass out. Someone got a wheelchair and we took her back to observation/treatment area. Patient was very drowsy, felt nauseous, hands were tingling, and was cold and clammy.  We asked her to text her Mom, who was sitting out in the parking lot, to have her come inside.  Pt reported passing out with HPV vaccine and on blood draws.  We moved patient to pt bed and took vitals (listed below).  Patient was able to recover without any medication administration under close observation.  After about 20 mins in obs/treatment area, she was feeling better and we moved her to the observation room with her Mom.  We had leftover vaccine syringes, so Mom received her first dose of vaccine.  They waited together until Mom's 15 mn obs time was over.  Patient and someone left the clinic feeling fine and under their own power around 1845.
vaccine was given then noted that it had expired the previous month 05/08/2022 vaccine was given 06/16/2022
Patient received the covid vaccine  dose #2 on 01/14/2021.  Two hours after vaccination, c/o new onset of nausea. No vomiting. Nausea is mild and persistence until today, 1/15/2021. She went to work but feel very "cold", bil leg weakness, and fatigue.   She had to end her work day today.  No fever, HA, dizziness, or any respiratory sxs
Pt. fully vaccinated with Pfizer COVID19 vaccine on 12/23/20 and 1/20/21.  Pt. reported COVID symptoms of sore throat, fatigue, loss of taste, loss of smell starting 9/9/21 and tested COVID positive via molecular swab on 9/10/21. EE then infected all household members.
stability problems; vertigo; tingling; chills; This spontaneous case was reported by a consumer and describes the occurrence of BALANCE DISORDER (stability problems), VERTIGO (vertigo), PARAESTHESIA (tingling) and CHILLS (chills) in a 79-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007M20A) for COVID-19 vaccination.     The patient's past medical history included No adverse reaction. Concomitant products included ACETYLSALICYLIC ACID (ASPIRIN (E.C.)) for an unknown indication.    On 18-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 18-Feb-2021, the patient experienced BALANCE DISORDER (stability problems), VERTIGO (vertigo), PARAESTHESIA (tingling) and CHILLS (chills). At the time of the report, BALANCE DISORDER (stability problems), VERTIGO (vertigo), PARAESTHESIA (tingling) and CHILLS (chills) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No treatment was reported.   Most recent FOLLOW-UP information incorporated above includes: On 11-May-2021: NNI, Per reporter - "You will have to make it easier to send back.  We couldn't return it". On 15-Jul-2021: Significant follow up received on 15-JUL-2021. Patient updated the outcome as resolved by stating 'No symptoms remain'.
Development of frozen shoulder in left arm.  Progressed from intense, painful tearing feeling to loss of mobility in joint.
This spontaneous report was received from a Licensed Vocational Nurse (LVN), referring to a patient of unknown age and gender. The patient's medical history, concurrent conditions, concomitant therapy, drug and allergy history were not provided. On an unknown date, the patient was vaccinated with an improperly stored dose of ROTATEQ (strength, dose number, dose and frequency were not reported) orally, lot number M041184, expiration date 31-MAY-2018, for prophylaxis. On an unspecified date, the vaccine was exposure to a temperature excursion; the data logger registered a temperature of 70.7° Fahrenheit (F) during a time frame of 2 hours and 36 minutes. There was not previous temperature excursion. No adverse effects were reported. This is one of several reports received from the same reporter. Sender's Comments: US-009507513-1710USA000593: US-009507513-1710USA011267: US-009507513-1710USA011268: US-009507513-1710USA011269: US-009507513-1710USA011270: US-009507513-1710USA011271: US-009507513-1710USA011272: US-009507513-1710USA011274: US-009507513-1710USA011275.
Redness, itching, swelling and bruising around the injection site. Concern this is the 4th day and it's not improving; Redness, itching, swelling and bruising around the injection site. Concern this is the 4th day and it's not improving; Redness, itching, swelling and bruising around the injection site. Concern this is the 4th day and it's not improving; Redness, itching, swelling and bruising around the injection site. Concern this is the 4th day and it's not improving; This is a spontaneous report from a contactable consumer, the patient. A 65-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6207) via an unspecified route of administration in the left arm on 06Apr2021 (at the age of 65-years-old) as a single dose for COVID-19 immunisation. Medical history included hypertension, chronic kidney disease stage 3 (reported as Kidney disease stage 3) and rheumatoid arthritis. The patient previously had lignocaine (reported as caines) and experienced drug allergy. Concomitant medication received within two weeks prior to vaccination included prescribed maintenance blood pressure and vitamin. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6204) via an unspecified route of administration in the right arm on 15Mar2021 at 09:00 (at the age of 65-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 06Apr2021 at 19:00 the patient experienced redness, itching, swelling and bruising around the injection site. She was concerned it was the fourth day and it was not improving. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the events redness, itching, swelling and bruising around the injection site was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Had injection late Friday afternoon (2/12/21). After going to bed that night, started feeling extreme body aches, chills, nausea, dizziness, with fever (101 temperature). According,  my heart rate went up dramatically overnight and was elevated all day on Saturday (showing 3 hours 16 minutes in exercise zone doing 19 minutes cardio and 2 hours 57 minutes fat burn although I was in bed all day).  It is important to note that on December 26th I tested Positive for Covid. I work for Health Care Agency and have been working at with option for Vaccine.
Telephone 9/1/2021 Family Medicine, Med Asst  Conversation Med Asst   9/1/21 2:08 PM  Called to check on patient due to the reason for his appt and that he had not shown up. I was unable to reach him. I called his wife and she was very emotional when answering the phone stating that she had found him on the floor and his o2 sat had gone into the 50's. She states that she called emergency services and that she was driving behind his ambulance to the hospital now. She added that he was not doing well and I told her that we all hopes he gets well soon.    ED to Hosp-Admission Current  9/1/2021 - present (7 days)  Hospital  Acute hypoxemic respiratory failure due to COVID-19 Severe sepsis  Patient is an 46 y.o. male.  With history of granulomatous lung disease who works as a EMT/firefighter who has received his first Covid vaccine 8/19/2021.  He had recent travel, and presents to the ED 9/1/2021 with complaint of shortness of breath.  He attempted to drive himself to the hospital via private vehicle but in route became more shortness of breath and EMS was activated.  On EMS arrival he had pulse ox in the 50s which improved to the 70s on CPAP.  On ED arrival he was severely short of breath and hypoxic.  He was trialed on BiPAP which was ultimately unsuccessful and he was intubated for respiratory failure.  Following intubation he had hypoxia, for which pulmonology was requested to assist prior to admission to the critical care unit.  Unable to perform ROS: Intubated  Central Line Date/Time: 9/1/2021 7:04 PM Performed by: CRNP Authorized by: CRNP    Insert arterial line Date/Time: 9/1/2021 7:04 PM Performed by: CRNP Authorized by: CRNP
Within the first 6 hours post-vaccination, I experience lip swelling and lip-tingling sensation.  by 12 hours, I started having excruciating blisters inside my lip and above my lip.  At the same time, I experienced a mild headache.  I reported all my symptoms to my MD  and asked if I can take anything for the painful blisters on my mouth and lip.  My Dr never called back; I received a message the next day through my chart to apply vaseline on my lip.   Within 1st 24h my discomfort and pain were getting worse, so per my mother's advice  (she is an MD), I started taking my husband's Acyclovir prescription and baby aspirin.  I massaged my Dr. she didn't address the issue, and I never received her thoughts on my decision to take Acyclovir.  On the 2nd-day post-vaccination, I started having more headaches and pulsating sensations in my R groin area. that lasted 7 days
Immune mediated FGFR3 and Plexin D1 Small fiber neuropathy  Burning in legs, full body nerve pain
Patient stated area around vaccine began getting red 2/16/21. It started as a small dot and has now grown to a "silver dollar size". The  area is raised, red and warm to the touch.
Right after receiving my second dose, I felt like I could taste the medicine. About forty five minutes later, I had an appointment and I was told I had a fever, but I felt fine. It was checked three times and each time I had a fever, but still felt fine. Around 8:00PM that night, I started to experience chills and I was sweating. My body started hurting really bad and I couldn't move anything on my left side. I got feeling back in my leg, but it was hurting. The numbness in my arm continued though two weeks and I could not move it. I went to Hospital ER on 03/08, because of my arm, but they told me that they couldn't do anything about my arm except give me pain medicine. I was told that my immune system is weak and my body is trying to fight. I am currently unable to move my right leg.
On the date of injection the left arm was very sore. The next day the army was very sore, I had a fever up to 102, and was very tired. No appetite. The third day I still had soreness, still had a slight fever 99.7, and the arm in yhe area of the shot was hot and red.
On 04/01/05, had bump at site of vaccination. 04/02/05-04/04/05 had 12 macular papular lesions (1 vesicular) on the right flank and buttock. A new one appearing on right wrist that is pruritic. Prescribed calamine lotion.
Received Expired Dose; This spontaneous case was reported by a physician and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Received Expired Dose) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 03-Dec-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 03-Dec-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Received Expired Dose). On 03-Dec-2021, EXPIRED PRODUCT ADMINISTERED (Received Expired Dose) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medications were not reported.
Information has been received from a Licensed Practical Nurse referring to a patient of unknown age and gender. Medical history and concurrent condition of the patient was not reported. On 15-AUG-2014 the patient was vaccinated with one dose of VAQTA (lot number reported as 5B23A, dose was unknown) intramuscularly which underwent an unsupported temperature excursion. No adverse effects reported. The lot number 5B23A is an invalid lot number for VAQTA. This is one of several reports received from same source. Additional information has been requested.
J96.00 ACUTE RESPIRATORY FAILURE 10/16/2021 ASPIRATION PNEUMONIA J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 10/19/2021 ASPIRATION PNEUMONIA
This case was reported by a consumer via call center representative and described the occurrence of shingles in a 71-year-old female patient who received SHINGRIX for prophylaxis. The patient's past medical history included shingles (previous diagnosis of shingles in August 2017). Previously administered products included ZOSTAVAX (previous ZOSTAVAX vaccination prior to August 2017). On 6th June 2018, the patient received the 1st dose of SHINGRIX .5 ml. On 9th June 2018, 3 days after receiving SHINGRIX, the patient experienced shingles and rash. In June 2018, the patient experienced pruritus. The patient was treated with acyclovir. On an unknown date, the outcome of the shingles, rash and pruritus were recovering/resolving. It was unknown if the reporter considered the shingles, rash and pruritus to be related to SHINGRIX. Additional details were provided as follows: Less than a week after receiving vaccination, the patient had an itchy back that she was told was shingles. This itching started several days prior to 9th June 2018, but the patient unsure when exactly that started. On 9th June 2018, Shingles rash was visible to the patient and then she went to the emergency room, where she was diagnosed with shingles and given 800 mg of acyclovir, then started on 400 mg of acyclovir three times a day for 30 days as treatment. The patient stated her PA told her this was due to the SHINGRIX vaccine, while her pharmacist disagreed, and stated this could not be from the SHINGRIX and it was not a live vaccine. The patient did not provide full demographics for herself or the pharmacy where the injection was given. The patient did not wish to participate in answering the questions within this report. No further adverse event information was provided.
could still see an outline of the arm rash; a giant red welt like rash at the injection site that looked like a burn; left arm was "really itchy"; a hive or two at the injection site; arm itched in general but not in a specific location; left arm started to hurt; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of PRURITUS (left arm was "really itchy"), RASH (could still see an outline of the arm rash), VACCINATION SITE URTICARIA (a hive or two at the injection site), VACCINATION SITE PRURITUS (arm itched in general but not in a specific location) and VACCINATION SITE RASH (a giant red welt like rash at the injection site that looked like a burn) in a 34-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Drug allergy (sulfa drugs, Augmentin.) and Drug allergy (amoxicillin-clavulanate).    On 21-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 21-Jan-2021, the patient experienced VACCINATION SITE PAIN (left arm started to hurt). On 28-Jan-2021, the patient experienced VACCINATION SITE URTICARIA (a hive or two at the injection site) and VACCINATION SITE PRURITUS (arm itched in general but not in a specific location). On 29-Jan-2021, the patient experienced PRURITUS (left arm was "really itchy") and VACCINATION SITE RASH (a giant red welt like rash at the injection site that looked like a burn). On 01-Feb-2021, the patient experienced RASH (could still see an outline of the arm rash). The patient was treated with ACRIVASTINE (BENADRYL OTC) at an unspecified dose and frequency and FAMOTIDINE (PEPCID [FAMOTIDINE]) at an unspecified dose and frequency. On 01-Feb-2021, PRURITUS (left arm was "really itchy"), RASH (could still see an outline of the arm rash), VACCINATION SITE URTICARIA (a hive or two at the injection site), VACCINATION SITE PRURITUS (arm itched in general but not in a specific location), VACCINATION SITE RASH (a giant red welt like rash at the injection site that looked like a burn) and VACCINATION SITE PAIN (left arm started to hurt) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Her HCP advised her to treat with OTC diphenhydramine and OTC famotidine. Unknown it the patient received second planned vaccine dose.
66 y/o F with PMH significant for severe COPD, pulmonary HTN, a-fib, pancreatic ca s/p Whipple, and dementia, who was initially admitted to the ICU for acute on chronic hypoxic respiratory failure from COVID-19 PNA requiring HFNC/NRB. Pt was treated with remdesivir and soul-medrol for her COVID-19 PNA. Her hospitalization was otherwise significant for a-fib with rvr, LLE DVT, and a new dx of chronic thrombus in the RLL artery . Pt was treated with anticoagulation with IV heparin. She was ultimately transferred out of the ICU after goals of care were addressed and her code status was changed to DNR/DNI. ICU consultation was requested by the primary team on 9/2 for escalating FiO2 requirements on HFNC. No dyspnea.
17 year old; This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (17 year old) in a 17-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 006B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 17-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 17-Mar-2021, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (17 year old). On 17-Mar-2021, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (17 year old) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Products known to have been used by the patient, within two weeks prior to the event were not provided.  No laboratory investigations were provided. The Treatment information and concomitant medication was not provided.
About 3 hours after my son received 3 vaccines in his thigh and one orally, he began to have a low grade fever (99.9) and just became very agitated and uncomfortable. These vaccines were given at his 4 month checkup as well as his 2 month check up in which he had the exact same reaction both times. He continued to be febrile for about 15 hrs post vaccine both times until the fever finally broke after treating with TYLENOL.